The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

People

Dr Martin Elhay

Dr Martin Elhay

Dr Martin Elhay

9035 4509 | martin.elhay@unimelb.edu.au

Position:
Senior Business Development Manager, Life Sciences Research, Innovation & Commercialisation
Theme(s):
Host Pathogens Interactions , Viral Infectious Diseases, Antimicrobial Resistance and Healthcare Associated Infections, Immunology
Discipline(s):
Discovery Research, Education & Professional Development, Epidemiology, Genomics, Indigenous Health, Public Health
Unit(s):
Department of Microbiology and Immunology (DMI), Doherty Directorate, The University of Melbourne

I have 7 years’ postdoctoral experience as an academic in human and animal health research (University of Melbourne, Faculty of Veterinary Science, Statens Serum Institute, Denmark) followed by over 15 years’ experience in industry (CSL Ltd, Pfizer Inc.). I have a track record of global and regional product and technology team leadership, new product development and commercializing pharmaceuticals and vaccines.

I provide business development services to The University of Melbourne, specifically to the Faculty of Medicine Dentistry and Health Sciences and the Faculty of Veterinary and Agricultural Science. I am well networked in the local and extended biotechnology, medical and veterinary industry. I have a strong interest in building the University’s capacity and skills in applied research and translation.

  • Key Achievements
    • Co-inventor of a vaccine for prevention of Hendra virus infection of horses (Elhay MJ and Broder C: Hendra and Nipah virus G glycoprotein immunogenic compositions, US Patent No. 61/485,992). Equivac™ HeV was launched in 2012.  As part of the Pfizer Hendra team received the National Australia Bank 2012 Agribusiness award for Excellence in Innovation.
      Commercialisation of a new vaccine, Canvac™CCi, for control of infectious tracheobronchitis (kennel cough) in dogs (launched 2006).
      Commercialisation of the world’s first vaccine, Equity™, for immunocontraception of horses and the first commercial vaccine using Iscomatrix® adjuvant (2002, Aust Vet J. 2007 Jan-Feb;85(1-2):39-45).
      Demonstration of Mycobacterium tuberculosis-specific diagnosis with peptides in an animal model (Infection and Immunity. 66:3454-3456. 1998).